Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.56 |
| ▸ | CES1 | P23141 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6518724 | 0.98 | CES2 (0.57) | CES2CES1ALDH1A1MAPK14L3MBTL1 | |
| SCHEMBL5744377 | 0.84 | CES2 (0.57) | CES2CES1 | |
| SCHEMBL14829993 | 0.83 | CES2 (0.61) | CES2CES1ALDH1A1L3MBTL1HTT | |
| SCHEMBL9340459 | 0.83 | CES2 (0.61) | CES2CES1ALDH1A1MAPK14L3MBTL1 | |
| SCHEMBL8292394 | 0.83 | CES2 (0.61) | CES2CES1ALDH1A1MAPK14L3MBTL1 | |
| SCHEMBL29993431 | 0.82 | DGAT1 (0.58) | CES2CES1ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL4110083 | 0.82 | DGAT1 (0.58) | CES2CES1ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL9046982 | 0.81 | CES2 (0.64) | CES2CES1ALDH1A1MAPK14L3MBTL1 | |
| SCHEMBL940243 | 0.81 | CES2 (0.64) | CES2CES1ALDH1A1MAPK14L3MBTL1 | |
| SCHEMBL7804388 | 0.81 | CES2 (0.59) | CES2CES1ALDH1A1MAPK14L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265606-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-10-21 | — | — | EP | disclosed |
| US-8163921-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | CES2 87/4885CES1 34/4885ALDH1A1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.